

Gille et al. 2023. <https://doi.org/10.1186/s12891-023-06923-8>

## Positive outcomes following Autologous Matrix-Induced Chondrogenesis (AMIC®) in the treatment of retropatellar chondral lesions: analysis of a patient registry

### Objective

- A retrospective analysis of patient outcomes from a multisite registry was conducted to assess the role of the AMIC® procedure in treating chondral defects on the retropatellar surface.

### Study Design



Prospective, multisite registry



64 patients (32 M/32 F) with symptomatic, focal, retropatellar chondral lesions, Outerbridge Grade III/IV treated with AMIC®.

- No concomitant surgery
- Mean lesion size: 3.1 cm<sup>2</sup>
- Mean age: 35.3 years
- Sport as the most common cause of cartilage injury



Mean follow-up (FU) of 5.8 years (range 1–10)

### Key Results


Of the 86 patients identified with retropatellar chondral lesions, the analysis included 64 patients who completed pre-op and at least one post-op measure of knee function and pain.

#### Clinical Outcomes

- Lysholm, pain VAS, and all KOOS domains improved significantly from pre-op to the first year post-op.
- The improvement was maintained throughout the FU period.

#### MCID and Responder Rate

- Improvements in the Lysholm score and all KOOS subscales were well above the MCID and with a high responder rate (> 80%), suggesting AMIC® to be an effective therapy.



### Conclusions

- The high forces exerted on the patellofemoral joint can make chondral repair challenging.
- However, this registry study shows that AMIC® is a robust and effective treatment for retropatellar chondral lesions, with significant and sustained improvements in function and pain.



Link to publication

## Chondro-Gide® Literature Highlight

This literature highlight addresses important aspects of the evidence for the use of Chondro-Gide®.

## XPERIENCE THE EVIDENCE

100+ peer-reviewed  
publications

Use  
AMIC® to treat  
retropatellar  
lesions!

### AMIC® Chondro-Gide®

- Combines bone marrow stimulating techniques with the collagen membrane<sup>1</sup>
- Biocompatible and naturally resorbed membrane<sup>1</sup>
- Easy to handle, supple and tear-resistant<sup>2</sup>
- Compatible with a range of cost-efficient, one-step cartilage regenerative techniques<sup>2,3,4</sup>
- Stable results over 10+ years<sup>5</sup>



More details about  
our products and  
distribution partners:



**Geistlich Pharma AG**  
Bahnhofstrasse 40  
6110 Wollhusen  
Switzerland  
ortho@geistlich.com  
www.geistlich-ortho.com

- 1 Geistlich Pharma AG, data on file (bench tests and pre-clinical studies)
- 2 Kramer J, et al., Cell Mol Life Sci. 2006 Mar;63(5):616-26. (Clinical study)
- 3 Walther M, et al., Oper Orthop Traumatol. 2014 Dec;26(6):603-10. (Clinical study)
- 4 Fossom V, et al., Orthop J Sports Med. 2019 Sep;7(9):2325967119868212. (Clinical study)
- 5 Kaiser N, et al., Arch Orthop Trauma Surg. 2021 Nov;141(11):1845-54. (Clinical study)